HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IRI challenges

This article was originally published in The Rose Sheet

Executive Summary

Information Resources, Inc. stockholder Chap-Cap Partners pushes for resignation of IRI Chairman, CEO and President Joseph Durrett or sale of the company in Feb. 13 filing with Securities & Exchange Commission. Chap-Cap Partners, which purchased 1.6 mil. shares of IRI recently, says IRI stockholders have been "gutted financially to the tune of 80%" since Durrett's "ill-fated" appointment to the post in May 1999. Durrett announced at a Feb. 7 analysts call that IRI is "exploring potential partners that might help expedite our progress" in better feeding client data needs and increasing return on stock equity. Termination of market research firm's contract with P&G will expire in June 2003 (1"The Rose Sheet" Dec. 16, 2002, In Brief). Total billings for P&G in 2002 accounted for less than 10% of U.S. revenue, IRI reports...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010974

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel